Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery

Impact of Baumann Skin Type on Wound Healing and Scar Formation Following Facial Skin Surgery

The goal of this observational study is to learn how an individual's skin type influences the wound healing process and scar formation in Chinese patients undergoing facial dermatologic surgery. The main questions it aims to answer are:

How does skin type affect the quality of wound healing after facial surgery?

How does skin type affect the formation of hypertrophic scars after facial surgery?

Researchers will compare groups of patients with different skin types (classified by the Baumann Skin Type) to see if there are significant differences in their healing outcomes and scar characteristics.

Participants in this study will:

Receive standard facial dermatologic surgery as part of their clinical care.

Have their skin type assessed preoperatively.

Undergo scheduled postoperative follow-up assessments at 7 and 90 days to evaluate wound healing and scar development using standardized scales.

Study Overview

• Status: Completed
• Conditions: Nevus; Scar; Lipoma; Seborrheic Keratosis (SK); Cyst

• Study Type: Observational
• Enrollment (Actual): 173

Contacts and Locations

Study Locations

• China
  • Hubei
    • Wuhan, Hubei, China, 430022
      • Not Appicable

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

patients undergoing facial skin surgery to remove benign lesions

Description

Inclusion Criteria:

• Aged between 14 and 60 years.
• Clinically and postoperatively pathologically diagnosed with a facial benign tumor (e.g., melanocytic nevus, sebaceous cyst, seborrheic keratosis, etc.) and having undergone standard surgical treatment.
• Voluntary participation in this study with written informed consent obtained.
• Commitment to comply with all study protocols and to complete all follow-up visits and data collection procedures.

Exclusion Criteria:

• Clinically or postoperatively diagnosed with a facial malignant tumor.
• Wounds requiring staged excision or planned for secondary intention healing.
• Surgical site located on or adjacent to the mucosal surface.
• Known history of allergy to any medications or dressings to be used during or after surgery.
• Presence of systemic diseases that significantly impair wound healing (e.g., poorly controlled diabetes, immunodeficiency disorders, active infections).
• Current use of medications affecting wound healing or scar formation (e.g., long-term systemic corticosteroids, immunosuppressants).
• Pregnancy or lactation.
• Refusal to provide written informed consent, or anticipated inability to comply with study follow-up and data collection.
• Concurrent participation in another interventional clinical trial.
• Any other condition deemed by the investigator as likely to interfere with study results or increase participant risk.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Oily Skin; classified as having oily skin according to the Baumann questionnaire
Dry Skin; classified as having dry skin according to the Baumann questionnaire

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Patient and Observer Scar Assessment Scale version 2.0 (POSAS 2.0)	This scale comprises two separate subscales: the Observer Scar Assessment Scale (completed by the clinician) and the Patient Scar Assessment Scale (completed by the participant). The Observer Scale evaluates six items (vascularity, pigmentation, thickness, relief, pliability, and surface area) on a scale from 1 ("like normal skin") to 10 ("the worst scar imaginable"), with a total score ranging from 6 (best) to 60 (worst). The Patient Scale evaluates six items (pain, itching, color, stiffness, thickness, and irregularity) on a scale from 1 ("no, not at all") to 10 ("yes, very much"), with a total score also ranging from 6 (best) to 60 (worst). For both subscales, a higher score indicates a worse scar quality.	3-month follow-up
modified Stony Brook Scar Evaluation Scale (mSBSES)	Evaluations were independently performed by two clinicians who were blinded to group allocation. The scale comprises four items: scar width, height, color, and suture marks. Each item is scored from 0 to 2 points, where a score of 2 represents the closest resemblance to normal skin, and 0 represents the worst appearance. The total score ranges from 0 to 8, with a higher score indicating a more ideal scar appearance.	3-month follow-up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Postoperative Edema	Assessed by direct clinical examination. Unit: % of participants with the presence of edema.	7-day follow-up
Incidence of Wound Suppuration	7-day follow-up	Assessed by direct clinical examination. Unit: % of participants with the presence of suppuration.
Incidence of Peri-wound Erythema	Assessed by direct clinical examination. Unit: % of participants with the presence of erythema.	7-day follow-up
Incidence of Wound Tenderness	Assessed by patient report. Unit: % of participants reporting tenderness.	7-day follow-up
Incidence of Postoperative Hemorrhage	Assessed by direct clinical examination. Unit: % of participants with active bleeding or hematoma formation.	7-day follow-up
Incidence of Peri-wound Ecchymosis	Assessed by direct clinical examination. Unit: % of participants with the presence of ecchymosis.	7-day follow-uo

Collaborators and Investigators

• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Study record dates

Study Major Dates

• Study Start (Actual): June 15, 2025
• Primary Completion (Actual): January 15, 2026
• Study Completion (Actual): January 15, 2026

Study Registration Dates

• First Submitted: January 18, 2026
• First Submitted That Met QC Criteria: January 28, 2026
• First Posted (Actual): February 3, 2026

Study Record Updates

• Last Update Posted (Actual): February 3, 2026
• Last Update Submitted That Met QC Criteria: January 28, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Neoplasms; Pathological Conditions, Anatomical; Neoplasms by Histologic Type; Skin Diseases; Neoplasms, Connective and Soft Tissue; Nevi and Melanomas; Neoplasms, Adipose Tissue; Keratosis; Fibrosis; Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases; Cicatrix; Cysts; Nevus; Lipoma; Keratosis, Seborrheic
• Other Study ID Numbers: WuhanUH-2025PFKBaumann